Pfizer (PFE) Quick Summary: Price $24.08 · 52W $23.11–$28.75 · Market cap ~$137B · Dividend $1.72/year · Yield ~7.1% · Ex-date July 24, 2026 · 351st consecutive quarterly dividend. The payout is tightly covered — cost discipline and pipeline delivery will determine whether it stays that way. Not a sleep-easy stock, but not an acute trap either.
By Marco Bozem · As of July 1, 2026 · Pharma Series #03
A 7.1% dividend yield sounds like a gift at first glance. But Pfizer is currently paying out roughly as much in dividends as it generates in free cash flow. That is the single most important question: is this a comeback dividend stock after the post-COVID crash — or a value trap dressed up in a generous yield?
I hold the stock myself, so let's look at this honestly.
Pfizer peaked near $60 in 2021. Today it trades around $24 — the stock has halved. And that collapse is exactly what produces the high yield. A high yield is never a buy reason by itself; it's a question: why is it this high?
The answer is in the revenue line. Pfizer generated roughly $100 billion in revenue in 2022 at the COVID peak. In 2025 that figure stood at $62 billion. Roughly $37 billion evaporated in two years — more than the company's entire pre-COVID annual revenue. The Comirnaty vaccine and Paxlovid collapsed, and earnings nearly disappeared in 2023. That is the reason for the share price collapse.
Pfizer's business rests on four pillars that determine whether the company can replace the revenue it is losing to patent expiries:
Pfizer pays $0.43 per quarter, $1.72 annually — the source of that 7.1% yield. One detail worth noting: the company just paid its 351st consecutive quarterly dividend and has raised it for 17 straight years. The next ex-dividend date is July 24, 2026, with payment on September 1, 2026.
The streak looks strong — but the annual increases have been token amounts, one cent per year. Pfizer is defending the streak, not genuinely growing the dividend.
Still — strained but not yet an acute trap. Three things are holding it: a $7.7 billion cost-savings program through 2027, management having already cut capital expenditures, and an oncology pipeline that must deliver. This is not a "buy and sleep" dividend compounder like a utility or REIT. It is a restructuring story that happens to pay you 7.1% while you wait. There is no margin of safety.
| Price (July 1, 2026) | $24.08 |
| 52-Week Range | $23.11 – $28.75 |
| Market Capitalization | ~$137B |
| Annual Dividend | $1.72 ($0.43/quarter) |
| Dividend Yield | ~7.1% |
| Ex-Dividend Date (Q3 2026) | July 24, 2026 |
| Payment Date (Q3 2026) | September 1, 2026 |
| Consecutive Quarterly Dividends | 351 |
| Payout Ratio (FCF basis) | ~100–110% |
| Net Debt | ~$66B |
| Net Debt / EBITDA | ~3.7x |
Pfizer acquired cancer specialist Seagen for roughly $43 billion in 2023, financed largely with approximately $31 billion in new debt. Net debt jumped from $34 billion to $68 billion; today it stands at about $66 billion. The net debt to operating profit ratio is around 3.7x — the upper end of the comfort zone, but interest coverage remains solid.
While attention focuses on the post-COVID revenue reset, the next revenue wave is already rolling in. Pfizer expects roughly $17–18 billion in revenue erosion by 2030 from patent expirations. Eliquis (blood thinner), Ibrance (breast cancer), and Xtandi (prostate cancer) all lose exclusivity by around 2028. That represents about a quarter of today's revenues.
Pfizer's defence consists of the Seagen oncology pipeline and the cost program. But those $7.7 billion in savings are a defence, not an offence. They are designed to stabilize profits while revenues erode from above. If savings materialize and the pipeline delivers, the equation works. If only one of those conditions holds, it will be tight. That is the central bet of the entire stock.
Activist investor Starboard Value accumulated roughly $1 billion in Pfizer shares late 2024 and pushed aggressively on management — too many poorly timed acquisitions, weak R&D productivity. Starboard exited by late 2025. The acute activist pressure is gone; the cost discipline it helped force remains.
More recently: Pfizer announced in June 2026 that CFO Dave Denton will leave the company on August 15. Cecile Guegan, SVP Finance for the Global Biopharmaceutical Business, has been named Interim CFO effective August 16. A CFO departure mid-cost-program introduces uncertainty into precisely the discipline this dividend depends on. Not a crisis, but a watch-list item.
Pfizer's own obesity drug danuglipron was discontinued in 2025 due to side effects. The answer: a $7 billion acquisition of specialist Metsera. The lead asset, a once-monthly injectable called berobenatide, reported Phase 2 data in June 2026 showing roughly 11% weight loss over 28 weeks. Solid data — but below what Eli Lilly and Novo Nordisk have demonstrated, and the market reaction was muted. This is Pfizer's bid to participate in the decade's biggest pharmaceutical trend — bought at a high price, outcome open.
US regulators have tightened access to COVID boosters, restricting them primarily to high-risk groups. For Pfizer's vaccines segment, this means lower volumes and more uncertainty — a structural headwind for what was once the company's primary cash cow.
On adjusted earnings, Pfizer trades at a P/E of around 9 — optically cheap if you trust the adjusted number. On a reported basis it is closer to 19, weighed down by Seagen amortization. EV/EBITDA is approximately 12, cheaper than Merck or AbbVie on this metric.
| Company | Dividend Yield | EV/EBITDA | Payout Risk |
|---|---|---|---|
| Pfizer (PFE) | ~7.1% | ~12x | High |
| Merck (MRK) | ~3.0% | ~14x | Low |
| AbbVie (ABBV) | ~3.2% | ~14x | Medium |
| Bristol Myers (BMY) | ~4.0% | ~10x | Medium |
Pfizer offers by far the highest yield in the peer group — but also the weakest dividend coverage and the highest leverage. High yield against high risk. That is the deal on the table.
Want the fundamental data behind this analysis?
I build my analyses with InvestingPro — fair value, financial health scores, FCF history and peer comparisons in one place. Use my link for 15% off, including on active promotions.
*Affiliate link — commission at no extra cost to you
I hold Pfizer myself — transparently tracked in my Parqet portfolio — and have collected several quarterly dividends over my holding period. The position is currently slightly in the red. I do not analyze stocks I do not own myself.
What I am still missing to turn genuinely bullish: concrete evidence that the oncology pipeline is replacing more revenue than the patent cliff takes away. That is not a bearish call — it is the condition the share price needs to move sustainably above $24.
Pfizer is not a "buy and forget" dividend stock. It is a show-me case. The 7.1% yield is real, but it comes without a margin of safety. Investors are betting on cost discipline and pipeline delivery. If that bet pays off, the reward is an outsized yield plus meaningful upside toward fair value. If it does not, a dividend cut eventually moves from risk to reality.
Independent investor focused on hard assets, dividend stocks and cashflow strategies. Areas of expertise: shipping, mining, energy, pharma. All analyses are based on original research and real portfolio positions. More about Marco
